TY - JOUR
T1 - Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis
AU - Chan, Chung Yin Stanley
AU - Browning, John C.
AU - Larsen, Fiona
AU - Hsu, Sylvia
PY - 2008/9
Y1 - 2008/9
N2 - Infliximab is a chimeric monoclonal antibody that selectively blocks tumor necrosis factor-alpha (TNF-α). It is indicated for the treatment of numerous inflammatory diseases, including rheumatoid arthritis, Crohn disease, ulcerative colitis, ankylosing spondyilitis, and psoriatic arthritis. Infliximab has also been shown to be a well tolerated and highly effective treatment for psoriatic skin lesions. We report an interesting case of unexpected, newonset psoriasis in a patient on infliximab for rheumatoid arthritis.
AB - Infliximab is a chimeric monoclonal antibody that selectively blocks tumor necrosis factor-alpha (TNF-α). It is indicated for the treatment of numerous inflammatory diseases, including rheumatoid arthritis, Crohn disease, ulcerative colitis, ankylosing spondyilitis, and psoriatic arthritis. Infliximab has also been shown to be a well tolerated and highly effective treatment for psoriatic skin lesions. We report an interesting case of unexpected, newonset psoriasis in a patient on infliximab for rheumatoid arthritis.
UR - http://www.scopus.com/inward/record.url?scp=54549105248&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=54549105248&partnerID=8YFLogxK
M3 - Article
C2 - 19061594
AN - SCOPUS:54549105248
VL - 14
JO - Dermatology Online Journal
JF - Dermatology Online Journal
SN - 1087-2108
IS - 9
M1 - 12
ER -